Older patients with IBD at higher risk for thiopurine-related adverse events

Among patients with inflammatory bowel disease older than 60 years, thiopurines were associated with an increased risk for non-infectious and non-neoplastic adverse events, according to study results.
Míriam Mañosa, of the IBD Unit at Hospital Universitari Germans Trias i Pujol in Spain, and colleagues wrote that starting immunosuppressant therapy in older patients with IBD can be difficult because of the associated comorbidities and polypharmacy.
“Physiological changes in the elderly patients may impact the pharmacokinetics of orally administered drugs,” they wrote in

Source link

Related posts

SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California


CDC: Uninsurance Levels Did Not Change Significantly in 2018


A route for pathology?


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World